Linaxin was founded in 2019 and is a national high-tech enterprise. It has established headquarters and research and development centers in Suzhou, as well as production bases and medical testing centers in Linyi and Binzhou. The company adheres to the concept of "technological innovation makes genes accessible", focuses on the independent research and development, intelligent manufacturing, and application of the new generation of solid-state nanopore gene detectors and supporting reagents, and is committed to becoming the creator of the new generation of nanopore gene detectors. Linaxin's medical health testing service platform provides next-generation nanopore gene testing applications and services.

Linaxin was jointly founded by domestic and foreign biomedical PhDs and gene sequencing scientists. It is a leading project in the development and industrialization of a new generation of portable nanopore gene detectors. Currently, it has a 12000 square meter R&D center, production base, and 3000 square meter medical testing center with GMP levels of 100000 and 10000. The company released the first domestically developed fourth generation solid-state nanopore gene detector Lsmart-SP1 prototype in 2022, which is the pioneer of China's first solid-state nanopore gene detector and the first domestically produced and independently developed new generation solid-state nanopore gene detector. In 2023, Lsmart-SP1 proprietary nanopore chip Cell-231 and supporting reagent kit were released. Lsmart-SP1 is an iPad sized handheld nanopore gene detector that integrates software and hardware. Specific reagents are mixed with 5 μ l of sample in the chip sample pool and tested for 10-15 minutes without amplification. The results can be directly read and reported, and it is applied in tumor early screening, companion diagnosis, pathogen detection, disease prognosis analysis, gene sequencing, etc.

Linaxin has the core process and production technology of nanopore chips, completed the mass production of the first generation Cell-231 chip, and developed the second generation Cell-241 chip, ushering in the era of high-throughput, low-cost, and miniaturized "mobile" gene detection, "ultra fast" era, and bringing detection sensitivity into the era of "single molecule recognition". Solid state nanopore technology with completely independent intellectual property rights, processing and preparation of nanopore biochips to micro nano fluid equipment, DNA molecule detection, solving bottleneck and international monopoly problems, filling the domestic gap.